The Prospects of Lipidic Prodrugs: An Old Approach with an Emerging Future

References

• Rautio J , MeanwellNA, DiL, HagemanMJ. The expanding role of prodrugs in contemporary drug design and development. Nat. Rev. Drug Discov.17(8), 559–587 (2018).
   PubMed Web of Science ®Google Scholar
• Stella VJ . Prodrugs as therapeutics. Expert Opin. Ther. Pat.14(3), 277–280 (2004).
   Web of Science ®Google Scholar
• Stella VJ , Nti-AddaeKW. Prodrug strategies to overcome poor water solubility. Adv. Drug Deliv. Rev.59(7), 677–694 (2007).
   PubMed Web of Science ®Google Scholar
• Testa B . Prodrugs: bridging pharmacodynamic/pharmacokinetic gaps. Curr. Opin. Chem. Biol.13(3), 338–344 (2009).
   PubMed Web of Science ®Google Scholar
• Huttunen KM , RaunioH, RautioJ. Prodrugs--from serendipity to rational design. Pharmacol. Rev.63(3), 750–771 (2011).
   PubMed Web of Science ®Google Scholar
• Irby D , DuC, LiF. Lipid-drug conjugate for enhancing drug delivery. Mol. Pharmaceut.14(5), 1325–1338 (2017).
   PubMed Web of Science ®Google Scholar
• Lambert DM . Rationale and applications of lipids as prodrug carriers. Eur. J. Pharm. Sci.11(Suppl. 2), S15–27 (2000).
   PubMedGoogle Scholar
• Markovic M , Ben-ShabatS, KeinanS, AponickA, ZimmermannEM, DahanA. Lipidic prodrug approach for improved oral drug delivery and therapy. Med. Res. Rev.39(2), 579–607 (2019).
   PubMed Web of Science ®Google Scholar
• Zaro JL . Lipid-based drug carriers for prodrugs to enhance drug delivery. Aaps J.17(1), 83–92 (2015).
   PubMed Web of Science ®Google Scholar
• Porter CJ , TrevaskisNL, CharmanWN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov.6(3), 231–248 (2007).
   PubMed Web of Science ®Google Scholar
• Nordskog BK , PhanCT, NuttingDF, TsoP. An examination of the factors affecting intestinal lymphatic transport of dietary lipids. Adv. Drug Deliv. Rev.50(1–2), 21–44 (2001).
   PubMed Web of Science ®Google Scholar
• Patton JS , CareyMC. Watching fat digestion. Science204(4389), 145–148 (1979).
   PubMed Web of Science ®Google Scholar
• Bernier-Latmani J , PetrovaTV. Intestinal lymphatic vasculature: structure, mechanisms and functions. Nat. Rev. Gastroenterol. Hepatol.14(9), 510–526 (2017).
   PubMed Web of Science ®Google Scholar
• Coert A , GeelenJ, DeVisser J, VanDer Vies J. The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen. Acta Endocrinol. (Copenh.)79(4), 789–800 (1975).
   PubMedGoogle Scholar
• Arakawa T , FukudaT, NakagawaKet al. Ulcerogenicity and effect on inhibition of prostaglandin generation of indometacin farnesil, a prodrug of indomethacin, in rat gastric mucosa: comparison with indomethacin or loxoprofen. Drugs Exp. Clin. Res.21(3), 85–88 (1995).
   PubMedGoogle Scholar
• Fernandez E , BorgstromB. Intestinal absorption of retinol and retinyl palmitate in the rat. Effects of tetrahydrolipstatin. Lipids25(9), 549–552 (1990).
   PubMed Web of Science ®Google Scholar
• Bibby DC , CharmanWN, CharmanSA, IskanderMN, PorterCJH. Synthesis and evaluation of 5′ alkyl ester prodrugs of zidovudine for directed lymphatic delivery. Int. J. Pharm.144(1), 61–70 (1996).
   Google Scholar
• Bala V , RaoS, BatemanE, KeefeD, WangS, PrestidgeCA. Enabling oral SN38-based chemotherapy with a combined lipophilic prodrug and self-microemulsifying drug delivery system. Mol. Pharm.13(10), 3518–3525 (2016).
   PubMed Web of Science ®Google Scholar
• Bala V , RaoS, LiP, WangS, PrestidgeCA. Lipophilic prodrugs of SN38: synthesis and in vitro characterization toward oral chemotherapy. Mol. Pharm.13(1), 287–294 (2016).
   PubMed Web of Science ®Google Scholar
• Shackleford DM , FaassenWA, HouwingNet al. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. J. Pharmacol. Exp. Ther.306(3), 925–933 (2003).
   PubMed Web of Science ®Google Scholar
• Tauber U , SchroderK, DusterbergB, MatthesH. Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone. Eur. J. Drug Metab. Pharmacokinet.11(2), 145–149 (1986).
   PubMed Web of Science ®Google Scholar
• Kandula M , SunilKumar KB, PalanichamyS, RampalA. Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases. Int. Immunopharmacol.40, 443–451 (2016).
   PubMed Web of Science ®Google Scholar
• Stuurman FE , VoestEE, AwadaAet al. Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors. Invest. New Drugs31(4), 959–966 (2013).
   PubMed Web of Science ®Google Scholar
• Sparreboom A , WolffAC, VerweijJet al. Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. Clin. Cancer Res.9(1), 151–159 (2003).
   PubMed Web of Science ®Google Scholar
• Rizzieri D , VeyN, ThomasXet al. A Phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. Leuk. Lymphoma55(9), 2114–2119 (2014).
   PubMed Web of Science ®Google Scholar
• Luo C , SunJ, LiuDet al. Self-assembled redox dual-responsive prodrug-nanosystem formed by single thioether-bridged paclitaxel-fatty acid conjugate for cancer chemotherapy. Nano Lett.16(9), 5401–5408 (2016).
   PubMed Web of Science ®Google Scholar
• Shackleford DM , PorterCJH, CharmanWN. Lymphatic absorption of orally administered prodrugs. In: Prodrugs: Challenges and Rewards Part 1. StellaVJ, BorchardtRT, HagemanMJ, OliyaiR, MaagH, TilleyJW. ( Eds)., Springer, New York, NY, USA, 653–682 (2007).
   Google Scholar
• Han S , HuL, Graciaet al. Lymphatic transport and lymphocyte targeting of a triglyceride mimetic prodrug is enhanced in a large animal model: studies in greyhound dogs. Mol. Pharm.13(10), 3351–3361 (2016).
   PubMed Web of Science ®Google Scholar
• Han S , QuachT, HuLet al. Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies. J. Control. Rel.177, 1–10 (2014).
   PubMed Web of Science ®Google Scholar
• Amory JK , ScribaGK, AmoryDW, BremnerWJ. Oral testosterone-triglyceride conjugate in rabbits: single-dose pharmacokinetics and comparison with oral testosterone undecanoate. J. Androl.24(5), 716–720 (2003).
   PubMedGoogle Scholar
• Paris GY , GarmaiseDL, CimonDG, SwettL, CarterGW, YoungP. Glycerides as prodrugs. 2. 1,3-Dialkanoyl-2-(2-methyl-4-oxo-1,3-benzodioxan-2-yl)glycerides (cyclic aspirin triglycerides) as antiinflammatory agents. J. Med. Chem.23(1), 79–82 (1980).
   PubMed Web of Science ®Google Scholar
• Sugihara J , FuruuchiS, AndoH, TakashimaK, HarigayaS. Studies on intestinal lymphatic absorption of drugs. II. Glyceride prodrugs for improving lymphatic absorption of naproxen and nicotinic acid. J. Pharmacobiodyn.11(8), 555–562 (1988).
   PubMedGoogle Scholar
• Radwan AA , AlanaziFK. Targeting cancer using cholesterol conjugates. Saudi Pharm. J.22(1), 3–16 (2014).
   PubMed Web of Science ®Google Scholar
• Wang H , FengZ, WuDet al. Enzyme-regulated supramolecular assemblies of cholesterol conjugates against drug-resistant ovarian cancer cells. J. Am. Chem. Soc.138(34), 10758–10761 (2016).
   PubMed Web of Science ®Google Scholar
• Dalpiaz A , PaganettoG, PavanBet al. Zidovudine and ursodeoxycholic acid conjugation: design of a new prodrug potentially able to bypass the active efflux transport systems of the central nervous system. Mol. Pharm.9(4), 957–968 (2012).
   PubMedGoogle Scholar
• Markovic M , Ben-ShabatS, KeinanS, AponickA, ZimmermannE, DahanA. Prospects and challenges of phospholipid-based prodrugs. Pharmaceutics10(4), 210 (2018).
   PubMed Web of Science ®Google Scholar
• Phan CT , TsoP. Intestinal lipid absorption and transport. Front. Biosci.6, D299–D319 (2001).
   PubMed Web of Science ®Google Scholar
• Dahan A , DuvdevaniR, ShapiroI, ElmannA, FinkelsteinE, HoffmanA. The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. J. Control. Rel.126(1), 1–9 (2008).
   PubMed Web of Science ®Google Scholar
• Kurz M , ScribaGK. Drug-phospholipid conjugates as potential prodrugs: synthesis, characterization, and degradation by pancreatic phospholipase A(2). Chem. Phys. Lipids107(2), 143–157 (2000).
   PubMed Web of Science ®Google Scholar
• Pedersen PJ , AdolphSK, SubramanianAKet al. Liposomal formulation of retinoids designed for enzyme triggered release. J. Med. Chem.53(9), 3782–3792 (2010).
   PubMed Web of Science ®Google Scholar
• Dahan A , DuvdevaniR, DvirE, ElmannA, HoffmanA. A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: in-vivo and in-vitro evaluation of an indomethacin-lecithin conjugate. J. Control. Rel.119(1), 86–93 (2007).
   PubMed Web of Science ®Google Scholar
• Dahan A , MarkovicM, EpsteinSet al. Phospholipid-drug conjugates as a novel oral drug targeting approach for the treatment of inflammatory bowel disease. Eur. J. Pharm. Sci.108, 78–85 (2017).
   PubMed Web of Science ®Google Scholar
• Dahan A , Ben-ShabatS, CohenNet al. Phospholipid-based prodrugs for drug targeting in inflammatory bowel disease: computational optimization and in-vitro correlation. Curr. Top. Med. Chem.16(23), 2543–2548 (2016).
   PubMed Web of Science ®Google Scholar
• Dahan A , MarkovicM, KeinanSet al. Computational modeling and in-vitro/in-silico correlation of phospholipid-based prodrugs for targeted drug delivery in inflammatory bowel disease. J. Comput. Aided Mol. Des.31(11), 1021–1028 (2017).
   PubMed Web of Science ®Google Scholar
• Markovic M , Ben-ShabatS, KeinanS, AponickA, ZimmermannEM, DahanA. Molecular modeling-guided design of phospholipid-based prodrugs. Int. J. Mol. Sci.20(9), 2210 (2019).
   PubMed Web of Science ®Google Scholar
• Markovic M , DahanA, KeinanSet al. Phospholipid-based prodrugs for colon-targeted drug delivery: experimental study and in-silico simulations. Pharmaceutics11(4), E186 (2019).
   PubMed Web of Science ®Google Scholar
• Pan D , PhamCTN, WeilbaecherKN, TomassonMH, WicklineSA, LanzaGM. Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery. Wiley Interdiscipl. Rev. Nanomed. Nanobiotechnol.8(1), 85–106 (2016).
   PubMed Web of Science ®Google Scholar
• Pan D , SanyalN, SchmiederAHet al. Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug. Nanomedicine (London, England)7(10), 1507–1519 (2012).
   PubMed Web of Science ®Google Scholar
• Rochon LS , DevarakondaK, MartinezJet al. Abstract CT230: a Phase I first in human dose escalation trial of MNK-010 in subjects with advanced solid tumors. Cancer Res.75(Suppl. 15), CT230 (2015).
   Google Scholar
• Schluep T , LickliterJ, HamiltonJet al. Safety, tolerability, and pharmacokinetics of ARC-520 injection, an RNA interference-based therapeutic for the treatment of chronic hepatitis B virus infection, in healthy volunteers. Clin. Pharmacol. Drug Dev.6(4), 350–362 (2017).
   PubMed Web of Science ®Google Scholar
• Nieschlag E . Current topics in testosterone replacement of hypogonadal men. Best Prac. Res. Clin. Endocrinol. Metab.29(1), 77–90 (2015).
   PubMed Web of Science ®Google Scholar